Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086706 | 0.88 | TACR2 (0.39) | GRIN1GRIN2BSSTR5TACR2TACR1 | |
| SCHEMBL1086351 | 0.85 | CYP2D6 (0.50) | USP2CYP1A2CYP2C9CYP2C19TACR2 | |
| SCHEMBL1086117 | 0.84 | RIPK1 (0.42) | USP2CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1086784 | 0.84 | TSHR (0.38) | USP2CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1086578 | 0.83 | USP2 (0.36) | USP2CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1086172 | 0.82 | TACR2 (0.42) | GRIN1GRIN2BSSTR5TACR2TACR1 | |
| SCHEMBL1086610 | 0.82 | HSD11B1 (0.47) | SSTR5CYP2C9CYP2C19TACR2TACR1 | |
| SCHEMBL1086781 | 0.81 | TACR2 (0.40) | GRIN1GRIN2BSSTR5TACR2TACR1 | |
| SCHEMBL1086543 | 0.80 | ITGB3 (0.39) | GRIN1GRIN2BSSTR5TACR2TACR1 | |
| SCHEMBL1085951 | 0.79 | FKBP1A (0.52) | CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | claimed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | claimed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | claimed |
| EP-1910381-A2 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-04-16 | — | — | EP | claimed |
| WO-2007000325-A2 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-01-04 | — | — | WO | claimed |
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-1910381-A2 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007000325-A2 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | GRIN1 238/4885GRIN2B 980/4885SSTR5 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.